<?xml version="1.0" encoding="UTF-8"?>
<ref id="B80">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jacobson</surname>
    <given-names>J. M.</given-names>
   </name>
   <name>
    <surname>Israel</surname>
    <given-names>R. J.</given-names>
   </name>
   <name>
    <surname>Lowy</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Ostrow</surname>
    <given-names>N. A.</given-names>
   </name>
   <name>
    <surname>Vassilatos</surname>
    <given-names>L. S.</given-names>
   </name>
   <name>
    <surname>Barish</surname>
    <given-names>M.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2004</year>). 
  <article-title>Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.</article-title>
  <source>
   <italic>Antimicrob. Agents Chemother.</italic>
  </source>
  <volume>48</volume>
  <fpage>423</fpage>â€“
  <lpage>429</lpage>. 
  <pub-id pub-id-type="doi">10.1128/aac.48.2.423-429.2004</pub-id>
  <pub-id pub-id-type="pmid">14742190</pub-id>
 </mixed-citation>
</ref>
